158 related articles for article (PubMed ID: 23634556)
21. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
Hurwitz H; Saini S
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
[TBL] [Abstract][Full Text] [Related]
23. The future development of bevacizumab in colorectal cancer.
Díaz-Rubio E; Schmoll HJ
Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
[TBL] [Abstract][Full Text] [Related]
24. Angiogenesis inhibitors in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
[TBL] [Abstract][Full Text] [Related]
25. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
26. Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
Coriat R; Mir O; Chaussade S; Goldwasser F
Dig Liver Dis; 2011 Mar; 43(3):248-9. PubMed ID: 21145299
[No Abstract] [Full Text] [Related]
27. Current role of bevacizumab in colorectal cancer.
Saltz L
Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
[No Abstract] [Full Text] [Related]
28. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
Giantonio BJ
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
[TBL] [Abstract][Full Text] [Related]
29. Avastin saga reveals debate over clinical trial endpoints.
Sharma SP
J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
[No Abstract] [Full Text] [Related]
30. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
Vaidyanathan G; Groman A; Wilding G; Fakih MG
Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
Zondor SD; Medina PJ
Ann Pharmacother; 2004; 38(7-8):1258-64. PubMed ID: 15187215
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
[TBL] [Abstract][Full Text] [Related]
33. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
34. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic therapy of colorectal cancer: state of the art, challenges and new approaches.
Sarmiento R; Longo R; Gasparini G
Int J Biol Markers; 2012 Dec; 27(4):e286-94. PubMed ID: 23280126
[TBL] [Abstract][Full Text] [Related]
36. Small reduction in quality of life seen with bevacizumab maintenance in patients with ovarian cancer.
Barton MK
CA Cancer J Clin; 2013; 63(4):219-20. PubMed ID: 23733586
[No Abstract] [Full Text] [Related]
37. Bevacizumab in elderly patients with metastatic colorectal cancer.
Sclafani F; Cunningham D
J Geriatr Oncol; 2014 Jan; 5(1):78-88. PubMed ID: 24484722
[TBL] [Abstract][Full Text] [Related]
38. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Krämer I; Lipp HP
J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
[TBL] [Abstract][Full Text] [Related]
40. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]